Skip to main content
PSTV
NASDAQ Life Sciences

Highmark涵盖Plus Therapeutics的CNSide检测，扩大报销范围至7500万人

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$0.156
Mkt Cap
$27.894M
52W Low
$3.225
52W High
$30.5
Market data snapshot near publication time

summarizeSummary

Plus Therapeutics宣布，其CNSide® CSF检测已获得Highmark的报销，这是一家主要的Blue Cross Blue Shield附属支付方。该协议将检测的报销范围扩大至约7500万人，这比之前增加了800万人。这是公司的一项积极的商业发展，近期公司面临着重大财务挑战，包括继续经营警告、纳斯达克摘牌风险和逆向股票拆分。扩大的覆盖范围预计将通过减少医生报销障碍来加速CNSide的采用，从而有助于公司实现2026年1.5亿覆盖人数的目标。这为收入增长提供了急需的积极催化剂，在面临财务困境的背景下，这一发展尤为重要。

在该公告发布时，PSTV的交易价格为$0.16，交易所为NASDAQ，所属行业为Life Sciences，市值约为$2789.4万。 52周交易区间为$3.23至$30.50。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed PSTV - Latest Insights

PSTV
Apr 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Blue Shield of California Covers Plus Therapeutics' CNSide® Assay, Expanding Access to 81 Million Lives
Sentiment: Positive
View Wiseek Article
PSTV
Apr 21, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Plus Therapeutics Regains Nasdaq Compliance, Resolving Delisting Risk
Sentiment: Positive
View Wiseek Article
PSTV
Apr 09, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Plus Therapeutics Appoints Dr. Eric J. Daniels as Chief Development Officer
Sentiment: Positive
View Wiseek Article
PSTV
Apr 08, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Plus Therapeutics Secures FDA Orphan Drug Designation for REYOBIQ in Pediatric Malignant Gliomas
Sentiment: Positive
View Wiseek Article
PSTV
Apr 02, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Plus Therapeutics Executes 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing
Sentiment: Negative
View Wiseek Article
PSTV
Apr 02, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Highmark Covers Plus Therapeutics' CNSide Assay, Expanding Reimbursement to 75 Million Lives
Sentiment: Positive
View Wiseek Article
PSTV
Mar 31, 2026, 4:20 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Shareholders to Vote on Major Equity Plan Expansion and Evergreen Provision
Sentiment: Neutral
View Wiseek Article
PSTV
Mar 31, 2026, 7:35 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Plus Therapeutics Announces Reverse Stock Split to Meet Nasdaq Listing Requirements
Sentiment: Negative
View Wiseek Article
PSTV
Mar 19, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
CNSide® Diagnostic May Cut Leptomeningeal Metastases Healthcare Costs by 40%, Boosting Commercialization Prospects
Sentiment: Positive
View Wiseek Article
PSTV
Mar 12, 2026, 4:29 PM EDT
Filing Type: 10-K
Importance Score:
9
Annual Report Reveals Going Concern, Nasdaq Delisting Risk, and Heavy Dilution from Recent Financings
Sentiment: Negative
View Wiseek Article